Valuation: Inovio Pharmaceuticals, Inc.

Market Cap 205M 184M 168M 154M 289M 19.29B 298M 2.03B 809M 10.29B 770M 754M 32.5B P/E 2026 *
-1.48x
P/E 2027 * -2.87x
Enterprise Value 205M 184M 168M 154M 289M 19.29B 298M 2.03B 809M 10.29B 770M 754M 32.5B EV / Sales 2026 *
-
EV / Sales 2027 * 3.82x
Free-Float
99.67%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Inovio Pharmaceuticals, Inc.

1 day-16.21%
1 week+101.69%
Current month+101.69%
1 month+5.19%
3 months+81.89%
6 months-11.31%
Current year-30.17%
1 week 1.07
Extreme 1.07
2.17
1 month 0.6
Extreme 0.5961
2.17
Current year 0.56
Extreme 0.5632
2.17
1 year 0.56
Extreme 0.5632
2.72
3 years 0.56
Extreme 0.5632
14.75
5 years 0.56
Extreme 0.5632
93.24
10 years 0.56
Extreme 0.5632
405.48
Manager TitleAgeSince
Chief Executive Officer 60 2022-05-09
Director of Finance/CFO 62 2002-05-31
Chief Tech/Sci/R&D Officer 60 2022-06-26
Director TitleAgeSince
Chairman 81 2019-01-02
Director/Board Member 69 2016-03-10
Director/Board Member 71 2017-12-05
Date Insider Type Main position Quantity % Market Cap. Importance
5/20/26 Free

Director

76,000 0.0928%
5/20/26 Exercice

Chief Technology Officer

75,817 0.0925%
5/20/26 Free

Chairman

76,000 0.0928%
Change 5-day change 1-year change 3-year change Capi.($)
-16.21%+101.69%-42.69%-73.43% 126M
-4.83%+3.51%+55.00%+63.79% 65.94B
+0.02%+1.07%+11.72%+75.63% 56.88B
-1.34%+2.98%+25.08%+100.18% 56.53B
+5.09%+9.89%+27.19%+105.85% 46.49B
+2.62%+1.68%+29.16%+35.86% 44.8B
+8.24%+0.51%+215.16%+794.74% 41.59B
-1.86%+10.13%+28.14%+55.48% 35.35B
-2.97%-9.84%+90.91%+73.49% 33.29B
+5.19%+1.62%-39.69%+368.87% 25.1B
Average -0.60%+12.55%+40.00%+160.05% 40.61B
Weighted average by Cap. +0.66%+3.10%+49.86%+165.99%

Financials

2026 *2027 *
Net sales - 53.77M 48.22M 44.07M 40.23M 75.8M 5.05B 78.19M 531M 212M 2.7B 202M 197M 8.51B
Net income -69.03M -61.91M -56.58M -51.65M -97.32M -6.49B -100M -682M -272M -3.46B -259M -254M -10.93B -54.42M -48.81M -44.61M -40.72M -76.72M -5.12B -79.14M -538M -214M -2.73B -204M -200M -8.62B
Net Debt - -
Projected Income Statement - Annual - Inovio Pharmaceuticals, Inc.
Logo Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
Employees
112
Date Price Change Volume
26-11-06 US$1.215 -16.21% 39,724,657
26-11-05 US$1.450 -10.49% 16,578,880
26-11-04 US$1.620 -2.41% 21,378,425
26-11-03 US$1.660 -12.17% 43,256,472
26-11-02 US$1.890 +213.75% 222,258,474
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Inovio Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.215USD
Average target price
5.333USD
Spread / Average Target
+338.96%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Inovio Pharmaceuticals, Inc.